Treatment

DEXMEDETOMIDINE , 18F-DPA-714 clinical trials

1 indexed studies · 0 currently recruiting

Ongoing, recruitingTherapeutic confirmatory (Phase III)
Impact of post-Acute respiratory distress syndrome COVID sedation on late neuroinflammation (PET-DEXDOCOVID)
This study looks at how a medicine called dexmedetomidine might help reduce long-term brain inflammation in COVID-19 patients who were very ill and needed breathing support. It aims to see if this medicine can improve their brain health after leaving intensive care.
For: Severe neuroinflammation is considered to be one of the main pathophysiological mechanisms causing delirium during ventilatory weaning. · In addition to its sedative properties, dexmedetomidine has neuroprotective effects. In certain experimental models, it reduces cerebral inflammation by acting directly on the microglial phenotype.
France